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Abstract
Background In the midst of the COVID-19 pandemic, patients have continued to present with endocrine (surgical)
pathology in an environment depleted of resources. This study investigated how the pandemic affected endocrine
surgery practice.
Methods PanSurg-PREDICT is an international, multicentre, prospective, observational cohort study of emergency
and elective surgical patients in secondary/tertiary care during the pandemic. PREDICT-Endocrine collected
endocrine-specific data alongside demographics, COVID-19 and outcome data from 11–3-2020 to 13–9-2020.
Results A total of 380 endocrine surgery patients (19 centres, 12 countries) were analysed (224 thyroidectomies, 116
parathyroidectomies, 40 adrenalectomies). Ninety-seven percent were elective, and 63% needed surgery within
4 weeks. Eight percent were initially deferred but had surgery during the pandemic; less than 1% percent was deferred
for more than 6 months. Decision-making was affected by capacity, COVID-19 status or the pandemic in 17%, 5% and
7%of cases. Indicationwas cancer/worrying lesion in 61% of thyroidectomies and 73% of adrenalectomies and calcium
2.80 mmol/l or greater in 50% of parathyroidectomies. COVID-19 status was unknown at presentation in 92% and
remained unknown before surgery in 30%. Two-thirds were asked to self-isolate before surgery. There was one COVID-
19-related ICU admission and no mortalities. Consultant-delivered care occurred in a majority (anaesthetist 96%,
primary surgeon 76%). Post-operative vocal cord check was reported in only 14% of neck endocrine operations. Both of
these observations are likely to reflect modification of practice due to the pandemic.
Conclusion The COVID-19 pandemic has affected endocrine surgical decision-making, case mix and personnel
delivering care. Significant variation was seen in COVID-19 risk mitigation measures. COVID-19-related compli-
cations were uncommon. This analysis demonstrates the safety of endocrine surgery during this pandemic.
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Introduction
The novel coronavirus disease 2019 (COVID-19) has
severely impacted the delivery of safe surgical care. During
the pandemic, although there was an overall depletion of
resources in hospitals, patients have continued to present
with surgical pathology. Consequently, this has resulted in
the large-scale disruption of elective surgical services
globally [1]. Currently, several studies are being carried out
to further understand the impact of the pandemic on the
delivery of surgical services at a subspecialty level [2, 3].
The World Health organization (WHO), National Health
Service (NHS) in the UK, American College of Surgeons
(ACS) and Royal Australasian College of Surgeons
(RACS), amongst others, have published specialty-specific
guidance on patient prioritization during the pandemic
[4–10]. However, the extent of adherence to these guide-
lines and its impact on patient care and outcomes has not
been fully reported.
PanSurg-PREDICT was founded by the PanSurg col-
laborative to build a novel risk prediction tool to provide
surgeons with more accurate estimates regarding the
potential risk of complications and mortality in patients,
with or without COVID-19 [11]. It collects and analyses
world-wide data regarding management and outcomes of
patients with surgical pathology, as well as the effects of
workforce planning and resource re-allocation in the con-
text of the COVID-19 pandemic. Specifically, in the field
of endocrine surgery, there is a paucity of data reporting on
the management of patients with endocrine surgical
pathology. The aim of this study was to evaluate which
patients were selected for endocrine surgery and what
precautions were taken to mitigate the risk of COVID-19.
Through this, we hope to gain an insight into endocrine
surgical practice during the pandemic and establish the
extent of COVID-19-related peri-operative morbidity.
Materials and methods
PanSurg-PREDICT is an international, multicentre,
prospective, observational cohort study of emergency and
elective surgical patients in secondary and tertiary care
during the pandemic. An open invitation to endocrine
surgery units was extended via the PanSurg website, social
media, to pre-existing PanSurg registrants in other spe-
cialties and via national endocrine societies. PREDICT-
Endocrine collected data for patients undergoing endocrine
surgery over a 6-month period from 21 March 2020 until
13 September 2020. Patient data collection required ethics
approval from the local Research and Development (R&D)
departments.
COVID-19 risk assessment
COVID-19 risk was assessed using results of swab tests;
imaging results; and self-isolation measures. COVID-19-
related morbidity, readmission to hospital or ICU, and
clinic follow-up details were also included.
Data collection
Data collection was performed on the GDPR-compliant
platform REDCAP [12, 13]. Data fields included baseline
demographic details, details of presentation, management
and operative assessment, surgery and outcomes, deferral
from surgery, influence on decision to admit and operate,
ICU and departmental capacity, prioritizing information
regarding emergency admissions, possible cancer diagno-
sis, multidisciplinary team discussion, TNM classification
and NHS priority levels. Endocrine-specific data were
incorporated within the overall PanSurg database including
indication for surgery, Thy/Bethesda classification, planned
procedure, surgical approach, voice changes, vocal cord
checks, blood loss, return to theatre, hypocalcaemia,
hypothyroidism and pathology reports. Patients were sub-
categorized into thyroid, parathyroid and adrenal cohorts.
Statistical analysis
Data were analysed using Microsoft Excel 2019 and Stata
MP 14 (Stata Corporation). All quantitative data are pre-
sented as median (range). The Chi-square test was used to
measure differences between patients with and without
COVID-19 mitigation measures with statistical signifi-
cance at p\ 0.05.
Results
Three hundred and eighty patients from 19 different centres
in 12 different countries were included (Supplementary
Table 1). In total, 224 thyroidectomies, 116 parathy-
roidectomies and 40 adrenalectomies were analysed.
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Characteristics of patients and operative case mix
(Table 1)
The median age of patients was 51 (17–90) years, with a
slightly older population undergoing parathyroidectomies
(58 (19–84) years). Female to male ratio was 2.39 in the
overall population, with a lower ratio for the adrenal
patients (1.35). Median BMI was 27 (16–49) kg/m2. Most
patients were White-Caucasian (65%), Asian (12%) or
Afro-Caribbean (6%) (p = 0.716). Sixty-two percent were
from UK centres, 27.11% Australia and the remainder from
Europe (Belgium, Greece, Hungary, The Netherlands,
Turkey), India and Middle Eastern countries. There was a
higher percentage of smokers undergoing adrenalectomies
(20%, n = 8) compared to thyroidectomies (9%, n = 18)
and parathyroidectomies (6%, n = 6) (p = 0.001). The
median ‘Clinical Frailty Score’ (CFS) was 2 (1–5). Fifty-
two percent of the patients were ASA grade II. The thy-
roidectomy cohort had more ASA I patients than the
parathyroidectomy and adrenalectomy groups (p = 0.003).
Eleven percent (n = 42) patients had a history of lung or
respiratory disease or symptoms.
Eleven patients (3%) presented as an emergency. Most
procedures were elective cases, including referrals for
possible malignancy (p = 0.294). Thirty-seven percent
(n = 142) underwent surgery for presumed cancerous
Table 1 Overview of the population characteristics
Population characteristics
Adrenal Parathyroid Thyroid Total
Age (median, yrs) 50 (18–77) 58 (19–84) 47 (17–90) 51 (17–90)
Gender (F:M ratio) 1.35 2.74 2.50 2.39
BMI (median, kg/m2) 25 (19–41) 27 (16–44) 26 (17–49) 27 (16–49)
Ethnicity (%)
 White 28 (70%) 71 (61%) 147 (66%) p = .716 246 (65%)
 Asian 2 (5%) 13 (11%) 29 (13%) 44 (12%)
 Black 3 (8%) 9 (8%) 12 (5%) 24 (6%)
 Other 7 (17%) 23 (20%) 36 (16%) 66 (17%)
Smoking status (%)
 Non-smoker 24 (60%) 90 (90%) 151 (77%) p = .001 265 (79%)
 Ex-smoker 8 (20%) 4 (4%) 27 (14%) 39 (12%)
 Smoker 8 (20%) 6 (6%) 18 (9%) 32 (9%)
Clinical Frailty Scale (median) 2 (1–5) 2 (1–7) 2 (1–9) 2 (1–9)
ASA (%)
 I 8 (20%) 29 (25%) 100 (46%) p = .003 137 (37%)
 II 25 (62%) 72 (63%) 99 (45%) 196 (52%)
 III 6 (15%) 12 (11%) 20 (11%) 38 (10%)
 IV 1 (3%) 1 (1%) 0 2 (1%)
Pos. Respiratory History 5 (12%) 7 (6%) 30 (14%) 42 (11%)
ECG Changes 0 8 (7%) 8 (4%) 16 (4%)
Presentation (%)
 Emergency 2 (5%) 5 (4%) 4 (2%) p = .296 11 (3%)
 Elective 38 (95%) 111 (96%) 220 (98%) 369 (97%)
Possible Cancer Diagnosis 16 (40%) 4 (3%) 122 (54%) 142 (37%)
MDT Discussion (%) 31 (78%) 15 (13%) 149 (67%) 195 (51%)
Deferred from Surgery (%) 5 (12%) 4 (3%) 22 (10%) 31 (8%)
NHS Priority Scale (%)
 1b 0 0 1 (1%) p = .294 1 (1%)
 2 18 (58%) 7 (47%) 97 (66%) 122 (62%)
 3 13 (42%) 8 (53%) 51 (33%) 72 (37%)
Patients (#) 40 116 224 380
‘#’ means number of patients
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lesions. This was higher in the thyroid group (54%) than
the adrenal (32%) or parathyroid (1,7%) cohorts. Half of
parathyroidectomies (n = 56) were performed in patients
with calcium 2.80 mmol/l or greater. Within the UK, over
60% of the operated patients were high risk and required
surgery within 4 weeks (NHS CPG 2). Only 1% (n = 1)
patient required urgent surgery within 72 h (NHS CPG 1).
This was a Graves’ patient with a severe thyroid storm and
a history of severe adverse effects from medical treatment.
Thirty-one patients (8.1%) had surgery deferred for
1–6 months, but 7.9% eventually underwent surgery. Only
1 patient was still awaiting his surgery at the end of the
inclusion period. The decision for surgery was most
affected by department capacity (17%) rather than the
pandemic itself (7%) or the patients’ COVID-19 status
(5%). Patient admission was influenced by department
capacity (8%), the pandemic itself (8%) and the patients’
COVID status (8%). Compared to the same time period in
2019, there was a 42% reduction in surgical procedures
during the pandemic.
COVID-19 risk mitigation strategies in endocrine
surgery patients (Fig. 1)
Most patients underwent a nasal/throat swab test (Supple-
mentary Table 2). Fifty-seven percent (n = 215) were
asked to self-isolate and had at least one COVID-19 test
prior to surgery. Fifteen percent (n = 59) self-isolated or
were tested pre-operatively. Twenty-eight percent
(n = 106) had an unknown COVID-19 status at time of
surgery and were not asked to self-isolate. Only 1 patient
underwent surgery with a known positive COVID-19 test
prior to surgery. This was again the Graves’ patient with
the thyroid storm.
Patients with a possible or confirmed cancer were not
more likely to undergo self-isolation and/or to get tested
pre-operatively (p = 0.185), and this was less likely in
emergency presentations than elective cases (p = 0.329).
However, there was a statistically significant difference in
the necessity for self-isolation and/or testing between dif-
ferent surgical procures (p = 0.003). Specifically, adher-
ence to risk mitigation measures was less in thyroidectomy
patients (p = 0.001); White-Caucasians and Asians
(p = 0.019); ex-smokers (p = 0.018); ASA I (p = 0.0001);
and lower priority guidance grouping (p = 0.001). No
statistically significant difference was found in emergency
presentation between the ‘measures’ and ‘no measures’
group (Table 2).
Observations of clinical behaviour
The indication for surgery was cancer or a worrying lesion
in a majority of thyroid and adrenal cases (Supplementary
Table 3) at 61% and 73%, respectively, including
phaeochromocytomas. Four patients (10%) had surgery for
a confirmed adrenocortical carcinoma. In the thyroid sur-
gery cohort, 137 patients (61%) had surgery for a worrying
lesion or confirmed cancer, including completion thy-
roidectomy for cancer. In this cohort, 116 total thyroidec-
tomies and 101 hemithyroidectomies were included (53%
vs 46%). Two Sistrunk’s procedures were performed (1%).
The indication for parathyroidectomy was primary
hyperparathyroidism in 95% (n = 109). Median serum
calcium level was 2.80 mmol/l (2.38–3.84 mmol/l). Three
percent (n = 4) patients had tertiary hyperparathyroidism.
Two percent patients (n = 2) had surgery for suspected
parathyroid cancer. Parathyroid surgery was a bilateral
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in the other 37% (n = 43). Two patients with malignancy
and originally planned for total thyroidectomy, underwent
a hemithyroidectomy due to invasion of the recurrent
laryngeal nerve (RLN) found at surgery in one and neu-
ropraxia in the other. This decision was taken to avoid the
potential for tracheostomy in the unlikely event of a
bilateral RLN palsy, specifically because there was concern
about how such a patient would fare if they contracted
COVID-19.
Consultant-delivered care was the norm during the
pandemic (Supplementary Fig. 1). An overwhelming 96%
(n = 338) procedures were performed under general
anaesthesia by a consultant anaesthetist. The primary sur-
geon was a consultant in 76% of procedures (293 out of
372). Of all procedures, 10% (n = 37) were joint cases with
2 consultant surgeons performing the surgery together.
Pre- and post-operative vocal cord checks in thyroid and
parathyroid surgery were evaluated (Table 3). Thirty-five
Table 2 Comparison between patient cohort with and without COVID-19 risk mitigation measures
Population characteristics measures/no measures
Measures No measures Chi-square (p values) Total
Age (median, yrs) 44 (19–85) 54 (17–90) 51 (17–90)
Gender (F:M ratio) 2.22 2.93 2.39
BMI (median, kg/m2) 26 (16–48) 28 (19–49) 27 (16–49)
Ethnicity (%)
 White 174 (64%) 72 (68%) p = .019 246 (65%)
 Asian 27 (10%) 17 (16%) 44 (12%)
 Black 23 (8%) 1 (1%) 24 (6%)
 Other 50 (18%) 16 (15%) 66 (17%)
Smoking status (%)
 Non-smoker 208 (81%) 57 (73%) p = .018 265 (79%)
 Ex-smoker 26 (10%) 13 (17%) 39 (12%)
 Smoker 24 (9%) 8 (10%) 32 (9%)
Clinical Frailty Scale (median) 2 (1–9) 2 (1–9)
ASA (%)
 I 89 (33%) 48 (46%) p = .0001 137 (37%)
 II 158 (59%) 38 (36%) 196 (52%)
 III 20 (7%) 18 (18%) 38 (10%)
 IV 2 (1%) 0 2 (1%)
Pos. Respiratory History 27 (10%) 15 (15%) 42 (11%)
ECG Changes 12 (4%) 4 (4%) 16 (4%)
Presentation (%)
 Emergency 6 (2%) 5 (5%) p = .188 11 (3%)
 Elective 268 (98%) 101 (95%) 369 (97%)
Possible Cancer Diagnosis 108 (39%) 34 (32%) 142 (37%)
MDT Discussion (%) 120 (44%) 75 (71%) 195 (51%)
Deferred from Surgery (%) 6 (2%) 1 (1%) 7 (2%)
NHS Priority Scale (%)
 1b 0 1 (1%) p = .001 1 (1%)
 2 86 (72%) 36 (48%) 122 (62%)
 3 34 (28%) 38 (51%) 72 (37%)
Indication (%)
 Adrenal 31 (11%) 9 (8%) p = .003 40
 Parathyroid 96 (35%) 20 (19%) 116
 Thyroid 147 (54%) 77 (73%) 224
Patients (#) 274 106 380
‘#’ means number of patients
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percent (n = 118) had a vocal cord check prior to surgery
and 14% (n = 44) afterwards. There was no statistically
significant difference between the thyroid and parathyroid
population (p = 0.759). A higher percentage of patients
had a pre-operative and post-operative vocal cord check in
the (possible) cancer group. In the study population with
COVID-19 risk mitigation measures, a larger number of
post-operative vocal cord checks were performed, in con-
trast with the higher number of pre-operative vocal cord
checks (p = 0.037). A follow-up appointment after surgery
was planned for 351 patients (98%).
Morbidity and mortality outcomes
There was no mortality recorded on short-term follow-up
(Table 4). Two vocal cord palsies (0.6%) were registered in
the thyroid and parathyroid group. After total thyroidectomy,
19% (n = 23) patients required calcium substitution. Four
percent (n = 5) parathyroidectomies (all bilateral explo-
rations) for primary hyperparathyroidism required calcium
replacement. The failure to cure rate was 5% for primary
hyperparathyroidism. There were 3 neck haematomas post-
operatively (0.9%): two that were managed conservatively
and one that required surgery for a compressive haematoma
post-total thyroidectomy. Five percent (n = 19) were admit-
ted to ICU post-operatively (14 planned and 5 unplanned).
The one patient that underwent surgery despite a known
concomitant diagnosis of COVID-19 went to ICU as he had a
severe thyroid storm prior to his surgery. Only 1 unplanned
ICU admission occurred due to a COVID-19 infection. One
other patient acquired COVID-19 while in hospital. Apart
from 2 patients who were transferred to another hospital, all
were discharged home (99%). Five patients (1%) were
readmitted to the hospital due to surgical morbidity, of which
only 1 patient required a readmission for a COVID-19 diag-
nosis between discharge and the first follow-up appointment.
Discussion
This international, multicentre, prospective, observational
cohort study of emergency and elective endocrine surgical
patients is the first to analyse world-wide data regarding
management of endocrine surgical patients, risk mitigation
measures and the associated outcomes during the COVID-
19 pandemic. Over a third of the 380 patients included in
the analysis underwent surgery for confirmed or possible
cancer. Nearly two-thirds of the patients were classified as
requiring surgery within 4 weeks to avoid adverse effects
on survival or progression. Eight percent of patients were
initially deferred from surgery. According to endocrine
surgeons, the pandemic was a considerable factor in the
decision to operate in one-third of the patients. Risk miti-
gation measures differed between countries, with one-third
not having to isolate before surgery and nearly one-third
having an unknown COVID-19 status at time of surgery.
Consultant-delivered care in a majority and post-operative
vocal cord checks in a minority are both likely to be
sequelae of the pandemic. For example, in the UK around
12% of parathyroidectomy cases and 14% of thyroid cases
Table 3 Pre- and post-operative vocal cord checks in thyroid and parathyroid surgery
Vocal cord checks overall
Pre-op Post-op
# % # % Chi-square
TOTAL 118 35% 44 14%
Thyroid 94 42% 36 17% p = .759
Parathyroid 24 21% 8 7%
Vocal cord checks covid-19 measures/no measures
Pre-op Post-op
# % # % Chi-square
Measures 68 28% 20 10% p = .037
No Measures 50 52% 5 5%
Vocal cord checks cancer/no cancer
Pre-op Post-op
# % # % Chi-square
Cancer 53 43% 25 22% p = .020
No Cancer 63 29% 12 6%
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are performed by a trainee in normal circumstances [14].
The reasons for this shift may be the redeployment of
junior staff to ICU or COVID wards or the perception that
consultant-delivered care would minimize surgical mor-
bidity. Whatever the reason, the effect on surgical and
anaesthetic training is concerning and will need to be
monitored. Post-operative vocal cord checks are reported
as being performed in 42% in the UK pre-COVID-19 [14],
and the authors surmise that the reason for few being
performed was their classification as an aerosol-generating
procedure (AGP). Despite the preponderance to malig-
nant/suspicious pathology and difference risk mitigation
strategies, there were minimal morbidity and no mortality.
Thus, endocrine surgery was safely delivered by a hands-
on senior clinical approach, despite the disruption and risks
caused by the pandemic.
Essential cancer treatments had to continue during the
pandemic. Based on national expert opinions, indications
for endocrine surgery were updated and recommendations
to postpone or prioritize certain procedures were made
[4–10]. In the UK, clinical guidelines classified patients
requiring surgery into four categories: emergency opera-
tions within 24 h; urgent operations within 72 h; elective
procedures within 4 weeks; and surgery delayed for
10–12 weeks without adverse outcomes [15–17]. In Aus-
tralia, the Royal Australian College of Surgeons classified
patients into four categories based on clinical urgency, with
category 1 requiring surgery before 6 weeks; category 2
before 12 weeks; and category 3 as more than 12 weeks.
Category 1 patients were prioritized for surgical interven-
tion during the initial phases of the pandemic [18]. In India,
the Association of Surgeons of India categorized patients
into three categories based on risk assessment and proposed
for surgery to proceed without delay for high-risk category
III patients but use a deferred approach for low-risk cate-
gory I patients for up to 6–8 weeks [19]. A similar
approach was also employed in other European countries,
including Germany, Italy and Netherlands [20–24]. Hence,
the prioritization of patients according to surgical risk and
weighing it against the risks of COVID-19 was essential to
ensure equitable allocation of surgical care.
From the 8% of patients initially deferred from surgery,
most underwent surgery within 3 months. Only one patient
had surgery delayed for over 6 months. Reasons for
deferral were varied: (a) not deemed sufficiently urgent
according to national guidelines; (b) lack of resources (e.g.
theatre staff/ICU bed unavailable due to COVID-19); and
(c) patient comorbidities make admission/surgery too high
risk at time of COVID-19. The decision to offer surgery to
a patient was most influenced by department capacity.
Hence, surgeons prioritized their patients based on guide-
lines but were restricted by theatre closures, ICU capacity,
ward capacity and/or staff shortages. Once this ‘restriction’
was overcome, the next critical factor for admission was
the patients’ COVID-19 status. Our results also show that
60% of cases were not affected by the department capacity
or the patient’s COVID-19 status. Thus, resources were
Table 4 Endocrine surgical morbidity during the COVID-19 pandemic
Endocrine surgical morbidity Adrenal Parathyroid Thyroid Total
# % # % # % # %
VC Palsy / / 1 1% 1 0.5% 2 0.6%
Hypoparathyroidism / / 5 4% 23 19% 28 12%
Failure to cure / / 5 5% / / 5 5%
Haematoma 0 0% 1 1% 1 0.4% 2 0.5%
Return to theatre 0 0% 0 0% 1 0.4% 1 0.3%
ICU Admission 9 23% 3 3% 8 3% 19 5%
 Planned 8 20% 1 1% 5 2% 14 4%
- COVID-19 related 0 0% 0 0% 1 0% 0 0.5%
 Unplanned 1 3% 2 2% 2 1% 5 1%
- COVID-19 related 0 0% 0 0% 1 0.4% 1 0.5%
Discharged home 40 100% 111 99% 116 99% 267 99%
Hospital readmission 2 5% 1 1% 2 1% 5 1%
 Surgery-related 2 5% 0 0% 2 1% 4 1%
 COVID-19-related 0 0% 1 1% 0 0% 1 0.5%
Hospital-acquired COVID-19 Infection 0 0% 0 0% 1 0.4% 1 0.5%
COVID-19 after discharge 0 0% 1 1% 0 0% 1 0.5%
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available to provide endocrine surgical care for patients
who required urgent and semi-urgent surgery.
Several strategies have been implemented to reduce the
risk of nosocomial COVID-19 transmission during their
inpatient stay with different success rates [25–28]. Sixty
percent of patients self-isolated pre-operatively. Seventy
percent of patients were tested for COVID-19 in the period
before surgery. Thirty percent of patients had an unknown
COVID-19 status at time of surgery, and only 7% within
this group self-isolated for 14 days. Comparing cohorts
with and without risk mitigation measures showed statis-
tically significant healthier patients (ASA I) and less urgent
procedures in the group without any mitigation measures.
More thyroid surgery was performed in the group without
measures, which could be attributed to a younger and
healthier cohort. Risk mitigation strategies varied between
countries, but not within centres. More post-operative
vocal cord checks were performed in the group with known
COVID-19 status, while fewer pre-operative vocal cord
checks were carried out in the group with risk measures.
This probably reflects the ‘fear’ related to a nasal flexible
endoscopy during the pandemic and a higher percentage of
patients having had their pre-operative vocal cord check
prior to the pandemic. Nasal flexible endoscopy is classi-
fied as an aerosol generating procedure with risk of viral
transmission in some centres [29, 30]. More vocal cord
checks were performed in the cancer population (with or
without neck dissection), being a known independent risk
factor for (temporary) nerve palsy [31]. The lack of vocal
cord checks may have influenced the low vocal cord palsy
rate after thyroid and parathyroid surgery. The incidence of
morbidity was rather small to generate statistically signif-
icant comparisons between the two cohorts. Most
adrenalectomies were laparoscopic or retroperitoneoscopic,
despite concerns of virus particles in surgical smoke [31].
There are some limitations to this study. Firstly, it only
includes endocrine surgery units, which tend to be located
within a tertiary centre and therefore generates a selection
bias, excluding any endocrine surgery which is performed
outside of a designated unit. We recognize that while this is
a multicentre study, a large proportion of the data is gen-
erated from a few countries specifically the UK and Aus-
tralia: this may be due to the high-volume nature of the
units submitting data in these countries or a reflection of
the severe impact of COVID-19 on the other countries.
This generates a degree of selection bias that limits the
generalizability of the data. Furthermore, two countries
within the same continent will have variation in the time-
line, incidence and management of COVID infections and,
most importantly, the broader structure of the healthcare
infrastructure, which can influence risk mitigation strate-
gies and patient prioritization. Since we have only reported
short-term follow-up data, any influence on cancer
outcome, permanent vocal cord palsy and hypoparathy-
roidism could not be fully addressed. Globally, most cen-
tres followed guidance which required a negative COVID
test result to qualify for surgery. The testing methodology
varied between centres and over the course of the pan-
demic, leading to varying levels of accuracy and stan-
dardization between different centres. This is yet another
confounding factor that we could not account for in this
study. Future work will focus on reporting the long-term
outcomes on morbidity and mortality; the variation in
COVID-19 risk mitigation measures; the reduction in sur-
gical services and the impact on surgical training.
Prospective data collection will continue to enable com-
parisons before and after peak incidence during the
pandemic.
Conclusion
The COVID-19 pandemic has a significant impact on
surgical management, patient selection and personnel
delivering surgical care. Despite a huge variation in
COVID-19 risk mitigation measures, COVID-19-related
complications were uncommon. This analysis demonstrates
the safety of endocrine surgery even during this pandemic.
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